Ansell share price set to benefit from coronavirus stockpiling

As grim as it seems, some companies stand to benefit from coronavirus stockpiling. Here's why Ansell Limited (ASX:ANN) may be one of them.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As grim as it seems, some companies stand to benefit from coronavirus stockpiling. In fact, facing threats like this is part of some companies' business models.

Ansell Limited (ASX: ANN) produces face masks, protective gloves, respirators and many other physical protection devices for industry and healthcare use. All of these are currently subject to stockpiling for coronavirus; an issue that may impact many of us. 

The Ansell share price fell 6% last week on the back of coronavirus fears. At the time of writing, Ansell shares have fallen another 1.18% today and are presently trading at $29.25 with a price to earnings (P/E) multiple of 17.8.

In the company's 1H20 earnings report, Ansell showed a lift in adjusted earnings before interest and tax (EBIT) by 4.8% against the previous corresponding period (pcp) and an 8.7% pcp increase in adjusted earnings per share (EPS).

The H1 report also called out the company's role in supplying personal protective equipment (PPE). In particular in China where Ansell is working with authorities to fast track its regulatory and import process in order to expedite supply.

Last Friday onn February 28, the company announced it had purchased more shares in its ongoing share buyback program which will add additional value to shareholders and boost EPS.

Over the past ten years, Ansell has demonstrated strong and consistent management in the PPE space. The Ansell share price has grown at a compound annual growth rate (CAGR) of 12% even though EPS has a 10-year CAGR of only 6.2%.

Stockpiling for coronavirus

Friday's Canberra Times article spoke of surgical masks being restricted at Brisbane airport due to limited supply. Even as early as the beginning of February, doctors were admonishing the public for stockpiling things like surgical masks.

These products are likely to face extra demand as long as coronavirus stockpiling continues. With the tragic fatality in Perth this weekend and the reports of stockpiling for coronavirus globally, I believe that the trend will continue. 

Foolish takeaway

During global health events, companies like Ansell are part of the emergency response team. These companies are built partly to fulfill the need that epidemic (and pandemic) scares like this create.

Given the global trend of stockpiling for coronavirus, Ansell is already coming under pressure to manufacture PPE for health workers and will likely see earnings per share increase regardless of any share buybacks. 

Motley Fool contributor Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »